Skip to content
CAPITAL STRUCTUREDrug Manufacturers - Specialty & Generic

Evonile Pharma Limited moves to reshape its capital structure

Evonile Pharma LimitedNOVARTIND

TL;DR

The effective discount cannot be quantified because the 30-day VWAP preceding the record date is not reported in the cited material. With an issue price of ₹860, the calculation is: `Discount = (30-day VWAP − ₹860) / 30-day VWAP` The rights issue proposes 10,287,832 shares at ₹860 each, for gross proceeds of ₹884.75 Cr.

What is the effective discount of the rights issue price relative to the 30-day volume-weighted average price (VWAP) preceding the record date, and how does the proposed issuance size impact the company's post-issue equity base and book value per share?

The effective discount cannot be quantified because the 30-day VWAP preceding the record date is not reported in the cited material. With an issue price of ₹860, the calculation is:

`Discount = (30-day VWAP − ₹860) / 30-day VWAP`

Capital-base impact

The rights issue proposes 10,287,832 shares at ₹860 each, for gross proceeds of ₹884.75 Cr [1]. Using 24,690,797 existing shares as the pre-issue base:

  • Post-issue shares: 34,978,629
  • Increase in shares: 41.7%
  • New shares as a percentage of post-issue shares: 29.4%
  • Dilution for a shareholder who does not participate: ownership falls to approximately 70.6% of the pre-issue percentage

The issue would therefore be sizeable relative to the existing equity base, although the proceeds are raised at a substantial premium to the ₹5 face value . On a nominal-capital basis, new share capital would add approximately ₹5.14 Cr, taking equity share capital from ₹12.34 Cr to approximately ₹17.48 Cr, before accounting for the partly-paid structure and issue mechanics [2] [1].

Book value per share: important source inconsistency

Using Q2 FY27 total equity of ₹771.72 Cr [3] and assuming full subscription, no issue costs and immediate recognition of the full proceeds:

  • Pro forma equity: ₹771.72 Cr + ₹884.75 Cr = ₹1,656.47 Cr
  • Pro forma book value per share: ₹1,656.47 Cr / 34,978,629 shares = approximately ₹473.6 per share

For reference, the same balance-sheet inputs imply pre-issue book value of approximately ₹312.6 per share, so the fully subscribed issue would be mathematically accretive to book value per share by approximately 51.5%, because the ₹860 issue price is well above the implied pre-issue book value.

However, the reported KPI book value per share is ₹62.54 [4]. That figure does not reconcile with ₹771.72 Cr of total equity and 24,690,797 shares: those inputs imply ₹312.6 per share. A mechanical calculation starting from the reported ₹62.54 would produce a different pro forma figure of roughly ₹297 per share. The ₹473.6 estimate is therefore the balance-sheet-and-share-count-consistent figure, but the company’s reported BVPS basis should be reconciled before treating it as definitive.

Per the 'Objects of the Issue' section in the Letter of Offer, what specific proportion of the proceeds is allocated to debt reduction versus working capital requirements, and how does this allocation align with the company's current debt-to-equity ratio and interest coverage metrics?

The cited Letter of Offer extract does not provide the exact rupee split in the “Objects of the Issue” section. It only indicates that most of the ₹884.75 Cr rights-issue proceeds would repay borrowings, with the balance intended for working capital [5] [1].

Using the debt figure as a proxy for the repayment allocation, the implied split would be:

  • Debt reduction: ₹796.01 Cr, or approximately 90.0% of the ₹884.75 Cr issue.
  • Working capital: the residual ₹88.74 Cr, or approximately 10.0%.

This calculation is derived from the issue size and current debt figures, not directly confirmed by the Objects-of-the-Issue table [1] [6].

The allocation is financially consistent with the latest balance-sheet metrics:

  • Debt-to-equity: approximately 1.03x, derived from ₹796.01 Cr total debt and ₹771.72 Cr total equity as of Q2 FY27 [6] [3].
  • Interest coverage: -4.99x in Q2 FY27, with TTM coverage of only 1.32x [7] [8].

Analytical implication: the heavily debt-oriented allocation is logical because leverage has become material relative to equity and the latest quarter did not generate sufficient operating profit to cover interest. The 10% working-capital component provides operating liquidity, but the principal objective appears to be balance-sheet repair rather than funding growth.

How does the proposed rights issue size and the stated utilization of funds compare to recent capital-raising activities by mid-cap pharmaceutical peers, specifically regarding the balance between funding R&D pipelines versus deleveraging the balance sheet?

Evonile’s proposed ₹884.8 Cr rights issue is materially more balance-sheet-led than R&D-led. The reported use is primarily repayment of borrowing incurred to acquire the Minipress XL brand, whereas no comparable rights issue or explicit R&D/deleveraging allocation was disclosed for the five rostered pharmaceutical peers for FY26-FY27.

Capital-raising comparison

The rights issue is therefore large relative to Evonile’s pre-issue capital base: approximately 1.15x Q2 FY27 total equity, derived from the ₹884.8 Cr issue size and ₹771.7 Cr standalone equity [1] [3]. It is also approximately 1.11x reported debt, derived from the same issue size and ₹796.0 Cr debt [1] [6]. This is a substantially different profile from a conventional pipeline-financing raise.

R&D versus deleveraging

  • Evonile: the disclosed rationale is predominantly balance-sheet repair and refinancing of an acquired established brand. The cited material does not quantify a separate R&D or new-product-development allocation; the unspecified residual should not be assumed to fund R&D.
  • Peers: no peer-specific rights issue proceeds, R&D allocation, or debt-repayment allocation was disclosed for FY26-FY27. Accordingly, there is no evidence of a peer capital-raising model that can be directly described as R&D-led.
  • Balance-sheet contrast: Unichem and, to a lesser extent, Kwality have meaningful net debt, making deleveraging a plausible economic objective if they were to raise capital. Shukra, Jeena Sikho and RPG had low debt or net cash, so their capital needs—if raised—would more likely require an operating, capacity or pipeline rationale; that rationale was not reported.

Conclusion: Evonile’s proposal stands out not because it provides a clearly larger R&D war chest, but because its stated use is unusually explicit and debt-oriented. The evidence supports a deleveraging/acquisition-financing transaction, while peer R&D-versus-debt funding mixes remain not disclosed rather than demonstrably R&D-led.

CompanyRecent capital raise and stated useQ2 FY27 balance-sheet contextAnalytical read
Evonile PharmaRights issue of ₹884.8 Cr, approximately ₹885 Cr, for 1,02,87,832 shares at a reported full issue price of ₹860 [1]. The Ken reported that most proceeds would repay borrowing used for the ₹1,250 Cr Minipress XL acquisition [5].Standalone debt was ₹796.0 Cr and net debt ₹547.8 Cr [6] [9].Clearly weighted toward deleveraging/acquisition-financing repair. No quantified R&D allocation was stated in the cited material.
Shukra PharmaceuticalsN/D — not disclosed for FY26-FY27.Consolidated debt and net debt were both ₹22.5 Cr [10] [11].Low absolute leverage; a hypothetical fund raise would not appear primarily driven by debt reduction based on the latest balance sheet, but no capital-allocation purpose was disclosed.
Jeena Sikho LifecareN/D — not disclosed for FY26-FY27.Debt was ₹0.3 Cr and net debt was negative ₹68.4 Cr, indicating net cash [12] [13].Balance-sheet deleveraging is not an evident funding requirement; no R&D-funding raise was disclosed.
Unichem LaboratoriesN/D — not disclosed for FY26-FY27.Debt was ₹474.6 Cr and net debt ₹317.6 Cr [14] [15].This is the peer where deleveraging would be most economically relevant after Evonile, but no recent equity raise or stated use of proceeds was reported.
Kwality PharmaceuticalsN/D — not disclosed for FY26-FY27.Debt was ₹146.2 Cr and net debt ₹144.4 Cr [16] [17].Some balance-sheet leverage exists, but there is no disclosed capital raise to assess against R&D spending.
RPG Life SciencesN/D — not disclosed for FY26-FY27.Debt was ₹22.3 Cr and net debt was negative ₹88.3 Cr, indicating net cash [18] [19].Deleveraging is not an apparent funding rationale; no R&D-oriented capital raise was disclosed.

Sources

  1. [1]Evonile Pharma Ltd — Outcome of the meeting of the Rights Issue Committee held to | BazaarWatch — Bazaarwatch, 2026-11-04T00:00:00
  2. [2]Equity Share Capital
  3. [3]Total Equity
  4. [4]Book Value Per Share
  5. [5]Novartis India’s headcount: 57. Chryscapital’s price for it: Rs 1,400 cr. Investors after the deal: “We love it” - The Ken — The Ken, 2026-11-09T00:00:00
  6. [6]Total Debt
  7. [7]Interest Coverage Ratio
  8. [8]TTM Interest Coverage Ratio
  9. [9]Net Debt
  10. [10]Total Debt
  11. [11]Net Debt
  12. [12]Total Debt
  13. [13]Net Debt
  14. [14]Total Debt
  15. [15]Net Debt
  16. [16]Total Debt
  17. [17]Net Debt
  18. [18]Total Debt
  19. [19]Net Debt

Keep digging

What is the effective discount of the rights issue price relative to the 30-day volume-weighted average price (VWAP) preceding the record date, and how does the proposed issuance size impact the company's post-issue equity base and book value per share?

Ask Copilot
Logo

Unlock financial AI for your firm